Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519495 | 1.00 | ACHE (0.32) | ACHEBACE1HTT | |
| SCHEMBL13242312 | 1.00 | ACHE (0.32) | ACHEBACE1HTT | |
| Pterosin Z SCHEMBL1742692 | 0.86 | ACHE (0.33) | ACHEBACE1 | |
| SCHEMBL29717665 | 0.84 | ACHE (0.32) | ACHEBACE1 | |
| SCHEMBL13242320 | 0.84 | ACHE (0.32) | ACHEBACE1 | |
| SCHEMBL13266404 | 0.79 | ACHE (0.32) | ACHEBACE1 | |
| SCHEMBL29717644 | 0.75 | ACHE (0.57) | ACHEBACE1 | |
| SCHEMBL29717584 | 0.75 | ACHE (0.67) | ACHEBACE1 | |
| SCHEMBL16489152 | 0.72 | HTT (0.30) | HTT | |
| SCHEMBL23062632 | 0.71 | NPSR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389171-B1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | UNIV TAIPEI MEDICAL (TW) | 2016-03-30 | — | — | EP | disclosed |
| US-8633252-B2 | Use of pterosin compounds for treating diabetes and obesity | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-01-21 | — | — | US | disclosed |
| US-8633252-B2 | Use of pterosin compounds for treating diabetes and obesity | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-01-21 | — | — | US | disclosed |
| US-8633252-B2 | Use of pterosin compounds for treating diabetes and obesity | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-01-21 | — | — | US | disclosed |
| EP-2389171-A2 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | Taipei Medical University (TW) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253556-A1 | SOLUTION SYSTEM FOR ELECTROLYTICALLY REMOVING TITANIUM CARBIDE COATING AND METHOD FOR SAME | FIH (HONG KONG) LIMITED (HK) | 2011-10-20 | — | — | US | disclosed |
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | US | disclosed |
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | US | disclosed |
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085811-A2 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085811-A2 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190732-A1 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY | PGC, PTMA, GPR119 | ACHE 3744/4885BACE1 4736/4885HTT 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.